Adavosertib
Adavosertib (pronounced as ada-vo-ser-tib) is a small molecule inhibitor that is currently under investigation for its potential use in the treatment of various types of cancer. It is specifically designed to inhibit the activity of Wee1, a protein kinase that plays a crucial role in the cell cycle.
Etymology
The name "Adavosertib" is derived from the pharmaceutical naming conventions, where "ada" is a prefix often used in drug names, "vo" is a infix used in oncology drugs, and "sertib" is a suffix used for kinase inhibitors.
Mechanism of Action
Adavosertib works by inhibiting the activity of Wee1, a protein kinase that regulates the cell cycle. By inhibiting Wee1, Adavosertib forces the cancer cells to undergo mitosis before they are ready, leading to cell death. This mechanism of action is particularly effective against cancer cells, which often have defects in their cell cycle checkpoints.
Clinical Trials
Adavosertib is currently in Phase II clinical trials for the treatment of various types of cancer, including ovarian cancer, breast cancer, and lung cancer. Early results from these trials have shown promising results, with some patients experiencing significant reductions in tumor size.
Related Terms
- Small molecule inhibitor
- Wee1
- Cell cycle
- Mitosis
- Phase II clinical trials
- Ovarian cancer
- Breast cancer
- Lung cancer
External links
- Medical encyclopedia article on Adavosertib
- Wikipedia's article - Adavosertib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski